Company HighTide Therapeutics, Inc.

Equities

2511

KYG4568L1023

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Hong Kong S.E. Other stock markets 09:09:05 07/06/2024 BST			5-day change	1st Jan Change
4.48 ^HKD	+0.45%		-12.33%	-65.43%

05-21	108,000,000 Shares of HighTide Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2024.	CI
04-03	HighTide Therapeutics Completes Patient Enrolment for Phase II Trial of Metabolic Modulator	MT

HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Companyâs core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.

Managers	Title	Age	Since
Li Ping Liu CEO	Chief Executive Officer	55	31/12/10
Koon Yin Sim DFI	Director of Finance/CFO	55	30/11/22
Cathryn Bennett CTO	Chief Tech/Sci/R&D Officer	-	-
Meng Yu BRD	Director/Board Member	42	03/05/15
Ru Bai PRN	Corporate Officer/Principal	39	05/02/12
Li Yu SEC	Corporate Secretary	48	27/02/18
Tian Wei Ma PRN	Corporate Officer/Principal	57	31/01/23
Pik Man Chu SEC	Corporate Secretary	27	12-10
Leigh Anne MacConell PRN	Corporate Officer/Principal	58	31/01/21

Members of the board	Title	Age	Since
Bo Tan BRD	Director/Board Member	51	-
Xun Zhu BRD	Director/Board Member	66	29/11/20
Jin Li BRD	Director/Board Member	59	-
Li Ping Liu CEO	Chief Executive Officer	55	31/12/10
Meng Yu BRD	Director/Board Member	42	03/05/15
Li Xiong Ma BRD	Director/Board Member	50	15/11/21
Feng Jiang BRD	Director/Board Member	45	15/11/22
Tak Wai Hung BRD	Director/Board Member	66	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	514,770,668	61,698,382 ( 11.99 %)	41,949,294 ( 8.149 %)	11.99 %

Name	Equities	%	Valuation
Li Li 23.61 %	121,515,210	23.61 %	76 M $
Li Ping Liu 16.70 %	85,956,631	16.70 %	53 M $
Hongtu Capital Pte Ltd. 8.880 %	45,713,592	8.880 %	28 M $
AIH Capital 5.328 %	27,428,154	5.328 %	17 M $
Li Xiong Ma 0.7296 %	3,755,544	0.7296 %	2 M $
Meng Yu 0.3397 %	1,748,688	0.3397 %	1 M $
Xun Zhu 0.1664 %	856,605	0.1664 %	532 286 $

Hightide Therapeutics, Inc.

18B-102, Zhonghaixin Innovation Ganli 2nd Road, Jihua Neighborhood

518112, Shenzhen

http://www.hightidetx.com

address HighTide Therapeutics, Inc.(2511)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.156 CNY

Average target price

15.62 CNY

Spread / Average Target

+275.86%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
HIGHTIDE THERAPEUTICS, INC.	-65.43%	295M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B

Bio Therapeutic Drugs